Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation
Abraham S. Kanate(HonorHealth), Robert Lowsky(Stanford University), Judith A. Shizuru(Stanford University), Jonathan Benjamin(Amgen (United States)), Samuel Strober(Palo Alto University), Saurabh Chhabra(Medical College of Wisconsin), Sally Arai(Stanford Medicine), Laura Johnston(Stanford Medicine), Ginna G. Laport(Stanford Blood Center), David B. Miklos(Stanford University), Holbrook E. Kohrt(Stanford University), Robert S. Negrin(Stanford University), Bradley Efron, Wen‐Kai Weng(Stanford University)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k